in this issue
Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
Pfizer and Ranbaxy Settle Lipitor Patent Dispute
11:37 AM MDT | June 23, 2008 | Deepti Ramesh
Pfizer (New York) and Ranbaxy Laboratories Ltd. (Gurgaon) say they have settled their patent dispute involving Pfizer’s Lipitor, the largest selling cholesterol-lowering drug worldwide with sales of $12.7 billion. The agreement provides Ranbaxy with a license to sell Atorvastatin, the generic version of Lipitor, in the U.S. starting November 30, 2011, and in Australia, Belgium, Canada, Germany, Italy, the Netherlands, and Sweden starting at various dates, the firms say. The agreement follows unconfirmed media reports earlier this month regarding the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee